Surrozen (SRZN)
Develops multifunctional Wnt-mimetic biologics for serious retinal vascular and inflammatory eye diseases.
Something off on this page? Send us feedback.
A clinical-stage biotechnology company developing SZN-8141 and SZN-8143 for retinal vascular and inflammatory eye disease. Its antibody-engineering platform also supports SZN-413, a Fzd4-targeted program developed with Boehringer Ingelheim.
Applies Wnt-pathway biology and antibody engineering to multifunctional biologics for serious ophthalmic diseases. The wholly owned pipeline centers on SZN-8141 and SZN-8143: SZN-8141 pairs Fzd4 agonism with VEGF antagonism for diabetic macular edema and wet age-related macular degeneration, while SZN-8143 also adds IL-6 antagonism for uveitic macular edema.
Research and development are conducted through one operating segment from South San Francisco. The current focus followed a 2025 decision to narrow the platform to ophthalmology and discontinue the liver program SZN-043. Clinical execution depends on advancing preclinical candidates through IND clearance and studies; SZN-413 is being developed with Boehringer Ingelheim.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Prior rating | Rating | Prior target | Target |
|---|---|---|---|---|---|---|
| Aug 20, 2026 | William Blair | Initiate | Outperform | |||
| May 7, 2026 | H.C. Wainwright | Target | $32 | $44 | ||
| Feb 19, 2026 | Cantor Fitzgerald | Target | $40 | |||
| Jan 3, 2025 | Guggenheim | Upgrade | Neutral | Buy | $45 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $102.0M · Total debt $6.3M · Total assets $115.6M · Shareholders' equity −$218.7M
- Revenue
- $5.0M
- Operating income
- −$10.4M
- Net income
- $50.2M
No dividends on record.
| Institutions58 holders · as of Mar 31, 2026 | 76.00% | 8.93M shares | |
| Insiders6 holders · as of Jun 16, 2026 | 17.60% | 2.07M shares | |
| Strategic holders3 holders · as of Jul 24, 2026 | 15.16% | 1.78M shares | |
| Adds to | 108.76% |
11.75M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Two share counts disagree (11.75M in the company's Sep 3, 2026 report, 7.48M elsewhere); stakes use the report.
These groups come from separate filings that can overlap, so they add to 108.76%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Tim KutzkeyInsiderdirector, 10 percent owner | 16.31% | 1.92M | Form 4filed Jan 20, 2026 ↗ |
TCG Crossover Management, LLCInstitution | 12.53% | 1.47M | 13Fas of Mar 31, 2026 |
Venrock Healthcare Capital Partners III, L.P.Institution | 10.25% | 1.21M | 13Gfiled May 15, 2026 ↗ |
5AM Partners VII, LLCStrategic | 9.89% | 1.16M | 13Gfiled May 15, 2026 ↗ |
RA Capital Management, L.P.Institution | 7.42% | 871,731 | 13Gfiled Feb 17, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more · Form 4 — an insider's transaction report
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| Jul 22, 2026 | TCG Crossover GP II, LLC | 10 percent owner | −162,500 | $21.25 |
| May 4, 2026 | Craig C. Parker | director, officer: Chief Executive Officer | −4,524 | $33.33 |
| May 4, 2026 | Charles O. Williams | officer: Chief Operating Officer | −2,036 | $33.33 |
| May 4, 2026 | Yang Li | officer: Exec. Vice President, Research | −1,584 | $33.33 |
| Mar 23, 2026 | TCG Crossover GP II, LLC | 10 percent owner | +15,223 | $24.90 |
- Regeneron
Established anti-VEGF treatment across wet AMD and DME
- Novartis (ADR)
Anti-VEGF intravitreal treatment in wet AMD and DME
- Amgen
Aflibercept biosimilar supplied for wet AMD and DME
- Ocular Therapeutix
Phase 3 intravitreal hydrogel program for wet AMD and diabetic retinal disease
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Surrozen | $23.79 | +5.41% | $169.0M | — | — | 14.7 | +408.7% |
| Regeneron | $851.82 | −0.02% | $87.78B | 21.1 | 14.1 | 5.7 | +16.7% |
| Novartis (ADR) | $162.45 | +0.01% | $308.79B | 24.5 | 17.3 | 5.6 | +0.9% |
| Amgen | $443.00 | +0.04% | $239.00B | 27.5 | 18.9 | 6.3 | +9.7% |
| Ocular Therapeutix | $10.98 | +0.64% | $2.39B | — | — | 45.8 | +0.1% |
| Median | 24.5 | 17.3 | 6.0 | +5.3% |